# A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST

> **NCT02776878** · NA · UNKNOWN · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 57 (estimated)

## Conditions studied

- Gastrointestinal Stromal Tumor

## Interventions

- **DRUG:** dasatinib

## Key facts

- **NCT ID:** NCT02776878
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-05
- **Primary completion:** 2017-10
- **Final completion:** 2018-05
- **Target enrollment:** 57 (ESTIMATED)
- **Last updated:** 2016-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02776878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02776878, "A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02776878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*